Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

Two Pharma JVs Start Operations in China: Hisun-Pfizer and Merck-Simcere

publication date: Sep 13, 2012
Two high-visibility generic drug JVs between east and west pharmas have commenced operations in China. Hisun Pharma and Pfizer have established their $295 million JV to produce branded generic drugs. At the same time, Merck and Simcere teamed up to concentrate on generic drugs for chronic ailments, especially cardiovascular and metabolic disease. Both were announced as letters of intent just over a year ago, and now they have become operational. More details....

Stock Symbols: (SHE: 600267) (NYSE: PFE) (NYSE: MRK) (NYSE SCR)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China